A drug originally developed to treat Alzheimer's disease may also help teenagers with autism improve their communication skills, according to a new study.The drug, called memantine (sold under the ...

MoonLake Immunotherapeutics recently announced that its Phase 3 VELA-2 trial for sonelokimab in hidradenitis suppurativa did not meet its primary goal due to a higher-than-expected placebo response, ...

Cemiplimab significantly improved disease-free survival in high-risk CSCC, reducing recurrence or death risk by 68% compared ...

House Speaker Mike Johnson has weighed in on the political debate over Bad Bunny being booked to play the 2026 Super Bowl halftime show, saying it was “a terrible decision” — echoing the beliefs of ...

A new pill called baxdrostat may offer hope for people whose blood pressure stays high even after taking standard medications ...

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...

Called sonelokimab, the product inhibits both the A and F isoforms of interleukin-17 (IL-17). In this mid-stage trial, well ...

The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma ...

Researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD) have completed a successful Phase 1 clinical trial of a novel vaccine designed to ...

The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of ...

The U.S. Food and Drug Administration on Wednesday cleared Regeneron Pharmaceuticals’ immunotherapy, Libtayo, as an add-on treatment for skin cancer patients at high risk of their disease returning ...

Cemiplimab (Libtayo; Regeneron Pharmaceuticals) has been approved as an adjuvant treatment for adult patients with cutaneous ...